- Home
- RVP vs BCAB Comparison
RVP vs BCAB Comparison
Compare RVP & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVP
- BCAB
- Stock Information
- Founded
- RVP 1994
- BCAB 2007
- Country
- RVP United States
- BCAB United States
- Employees
- RVP N/A
- BCAB N/A
- Industry
- RVP Medical/Dental Instruments
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- RVP Health Care
- BCAB Health Care
- Exchange
- RVP Nasdaq
- BCAB Nasdaq
- Market Cap
- RVP 19.8M
- BCAB 21.6M
- IPO Year
- RVP 2001
- BCAB 2020
- Fundamental
- Price
- RVP $0.85
- BCAB $0.45
- Analyst Decision
- RVP
- BCAB Hold
- Analyst Count
- RVP 0
- BCAB 3
- Target Price
- RVP N/A
- BCAB $1.00
- AVG Volume (30 Days)
- RVP 97.6K
- BCAB 561.4K
- Earning Date
- RVP 08-14-2025
- BCAB 08-07-2025
- Dividend Yield
- RVP N/A
- BCAB N/A
- EPS Growth
- RVP N/A
- BCAB N/A
- EPS
- RVP N/A
- BCAB N/A
- Revenue
- RVP $38,161,712.00
- BCAB $11,000,000.00
- Revenue This Year
- RVP N/A
- BCAB N/A
- Revenue Next Year
- RVP N/A
- BCAB N/A
- P/E Ratio
- RVP N/A
- BCAB N/A
- Revenue Growth
- RVP N/A
- BCAB N/A
- 52 Week Low
- RVP $0.56
- BCAB $0.24
- 52 Week High
- RVP $0.97
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- RVP 70.65
- BCAB 65.33
- Support Level
- RVP $0.75
- BCAB $0.35
- Resistance Level
- RVP $0.87
- BCAB $0.38
- Average True Range (ATR)
- RVP 0.04
- BCAB 0.03
- MACD
- RVP 0.00
- BCAB 0.01
- Stochastic Oscillator
- RVP 85.71
- BCAB 90.66
About RVP Retractable Technologies Inc.
Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The company's products are the VanishPoint 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the small diameter tube adapter; the blood collection tube holder; the allergy tray; the IV safety catheter; the Patient Safe syringes; the Patient Safe Luer Cap; the VanishPoint Blood Collection Set; and the EasyPoint needle, as well as a standard 3mL syringe packaged with an EasyPoint needle. The company also sells VanishPoint autodisable syringes in the international market in addition to the Company's other products.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.